These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 15486204)
1. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Kasparkova J; Fojta M; Farrell N; Brabec V Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. Brabec V; Kasparkova J; Kostrhunova H; Farrell NP Sci Rep; 2016 Aug; 6():28474. PubMed ID: 27574114 [TBL] [Abstract][Full Text] [Related]
3. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899 [TBL] [Abstract][Full Text] [Related]
4. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909 [TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of polynuclear platinum anti-cancer agents. Roberts JD; Peroutka J; Farrell N J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354 [TBL] [Abstract][Full Text] [Related]
6. Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. Kasparkova J; Pospisilova S; Brabec V J Biol Chem; 2001 May; 276(19):16064-9. PubMed ID: 11279186 [TBL] [Abstract][Full Text] [Related]
7. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex. Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702 [TBL] [Abstract][Full Text] [Related]
8. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. Zehnulova J; Kasparkova J; Farrell N; Brabec V J Biol Chem; 2001 Jun; 276(25):22191-9. PubMed ID: 11303029 [TBL] [Abstract][Full Text] [Related]
9. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis. Kabolizadeh P; Ryan J; Farrell N Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160 [TBL] [Abstract][Full Text] [Related]
10. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Servidei T; Ferlini C; Riccardi A; Meco D; Scambia G; Segni G; Manzotti C; Riccardi R Eur J Cancer; 2001 May; 37(7):930-8. PubMed ID: 11313183 [TBL] [Abstract][Full Text] [Related]
11. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells. Zhu G; Myint M; Ang WH; Song L; Lippard SJ Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and activity of three new trinuclear platinums with cis-geometry for terminal metal centres. Hamad SA; Beale P; Yu JQ; Huq F J Biomed Sci; 2014 May; 21(1):41. PubMed ID: 24884683 [TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. O'Neill CF; Hunakova L; Kelland LR Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899 [TBL] [Abstract][Full Text] [Related]
14. DNA compaction by mononuclear platinum cancer drug cisplatin and the trisplatinum anticancer agent BBR3464: Differences and similarities. Banerjee T; Dubey P; Mukhopadhyay R Biochimie; 2012 Feb; 94(2):494-502. PubMed ID: 21893159 [TBL] [Abstract][Full Text] [Related]
15. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475 [TBL] [Abstract][Full Text] [Related]
16. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. Roberts JD; Peroutka J; Beggiolin G; Manzotti C; Piazzoni L; Farrell N J Inorg Biochem; 1999 Oct; 77(1-2):47-50. PubMed ID: 10626353 [TBL] [Abstract][Full Text] [Related]
17. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637 [TBL] [Abstract][Full Text] [Related]
18. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490 [TBL] [Abstract][Full Text] [Related]
19. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Brabec V; Kasparkova J Drug Resist Updat; 2005 Jun; 8(3):131-46. PubMed ID: 15894512 [TBL] [Abstract][Full Text] [Related]
20. Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites. Qu Y; Scarsdale NJ; Tran MC; Farrell NP J Biol Inorg Chem; 2003 Jan; 8(1-2):19-28. PubMed ID: 12459895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]